# Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)

> **NCT06121830** · PHASE3 · UNKNOWN · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 324 (estimated)

## Conditions studied

- Non-erosive Reflux Disease
- Non-Erosive Gastro-Esophageal Reflux Disease
- Non-Erosive Esophageal Reflux Disease

## Interventions

- **DRUG:** DWP14012 20mg
- **DRUG:** DWP14012 40mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06121830
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-31
- **Primary completion:** 2025-01
- **Final completion:** 2025-03
- **Target enrollment:** 324 (ESTIMATED)
- **Last updated:** 2023-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06121830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06121830, "Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06121830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*